Rigel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Rigel Pharmaceuticals

01/08/2023 23:02

* Rigel Pharmaceuticals Inc  RIGL.OQ  reported a quarterly
adjusted loss of 4 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 8 cents per share.
    * Revenue fell 9.8% to $26.89 million from a year ago;
analysts
expected $25.70 million. 
    * Rigel Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 4 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Rigel Pharmaceuticals Inc shares had risen by 7.0% this
quarter and lost 8.0% so far this year.
    * The company reported a quarterly loss of $6.6 million.
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 1 at 10:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.08          -0.04          Beat
 Mar. 31 2023      -0.10          -0.08          Beat
 Dec. 31 2022      -0.11          0.01           Beat
 Sep. 30 2022      -0.13          -0.11          Beat